Back to top

Susana Rives Sola

Susana Rives Sola, haematologist SJD Barcelona Children's Hospital

Susana Rives Sola

Languages:
Spanish, Catalan, English and French

You'll find me in

Oncology Bone Marrow Transplantation Laboratory
Pediatric haematologist
Expert in:
Pediatric acute lymphoblastic leukaemia. Immunotherapy in acute leukaemia
Languages:
Spanish, Catalan, English and French

Since 2000 I have worked as a specialist physician in the Paediatric Oncology Department of SJD Barcelona Children's Hospital and I'm head of the Hematopoietic System Tumors Unit. I combine healthcare with research. Among my main areas of interest are pediatric Acute Lymphoblastic Leukaemia (ALL) and pediatric Philadelphia-positive leukaemias, as well as CAR-T therapy. I have been a member of the Spanish Society of Pediatric Haematology and Oncology (SEHOP) ALL production committee since 2013, where I coordinate, together with Dr José Luis Dapena, the Leukemia group. I am also the Spanish delegate in the international paediatric leukaemia and lymphoma group at the International BFM-SG. I currently coordinate the SEHOP working group for the registration of Philadelphia-positive chronic myeloid leukaemia. Expert in ALL and CAR T-cell therapy, I am the principal investigator of five CAR-T therapy clinical trials (academic and pharmaceutical industry) for paediatric acute lymphoblastic leukaemia.

You'll find me in

Oncology Bone Marrow Transplantation Laboratory

Education

  • Doctoral thesis: "Clinical characterisation and prognostic factors in subgroups of paediatric patients with acute lymphoblastic leukaemia at a high risk of relapse". University of Barcelona, 2013.
  • Specialist in Haematology and Haemotherapy, Hospital Clínic Barcelona, 1995.
  • Bachelor's degree in Medicine and Surgery, University of Barcelona, 1994.

International experience

  • Placement in the Cancer Immunotherapy department of the Children's Hospital of Philadelphia (United States), 2014.
  • Placement in the Leukaemia and Lymphoma department of the Saint Jude Children's Research Hospital (United States), 2001.

Scientific activity

  • Spanish delegate in the International BFM-SG paediatric leukaemia and lymphoma group.
  • Member of the Spanish Society of Pediatric Haematology and Oncology ALL treatment protocol development committee (SEHOP/ALL 2013).
  • Coordination of the SEHOP chronic myeloid leukaemia working group.
  • Member of the Spanish Society of Pediatric Haematology and Oncology committee for the treatment and diagnosis of falciform cell anaemia (SEHOP/ECF 2010).
Publications
  • Maude SL., Laetsch TW., Buechner J., Rives S., Boyer M., Bittencourt H., Bader P, Verneris MR., Stefanski HE., Myers GD., Qayed M., De Moerloose B., Hiramatsu H., Schlis K., Davis KL., et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. Infusion of tisagenlecleucel in a planned analysis in 75 patients with lymphoblastic leukemia. The general remission rate in 3 months was 81%. New England Journal of Medicine, 2018; 378(5):439-448. doi: 10.1056/NEJMoa1709866.
  • Alonso-Saladrigues A., Català A., Berrueco R., Camós M., Torrebadell M., Rives S.: Aplastic crisis secondary to parvovirus B19 infection as the first manifestation of an undiagnosed hereditary spherocytosis: report of a pediatric series of spanish patients. Journal of Pediatric Hematology/Oncology, 2016 January; 38 (1): 81-2
  • Bautista F., Gallego S., Cañete A., Mora J., Diaz de Heredia C., Cruz O., Fernández J.M., Rives S., Madero L., Castel V., Cela M.E., Ramírez G., Sábado C., Acha T., Astigarraga I., Sastre A., Una Muñoz, Guibelalde M., Moreno L. Landscape of early clinical trials for childhood and adolescence cancer in Spain. Clinical and Translational Oncology, 2015 October 21. E-pub ahead of print.
  • Berrueco R., Alonso-Saladrigues A., Martorell-Sampol L., Català-Temprano A., Ruiz-Llobet A., Toll T., Torrebadell M., Naudó M., Camós M., Rives S. Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome. Usefulness of UGT1A1 mutational screening. Pediatric Blood & Cancer, 2015 62: 1195-201. 
  • Bento C., Percy M.J., Gardie B., Maia T.M., van Wijk R., Perrotta S., Ragione F.D., Almeida H., Rossi C., Girodon F., Aström M., Neuman D., Schnittger S., Landin B., Minkov M., Randi M.L., Casadevall N., et al. Genetic basis of congenital erythrocytosis: mutation update and online databases. Human Mutation, 2014; 35: 15-26.
  • Rives S., Camós M., Estella J., Gómez P., Moreno M.J., Vivanco J.L., Melo M., Fernández-Delgado R., Verdeguer A., Fernández-Teijeiro A., Lendínez F., López-Almaraz R., Uriz J.J., Badell I. Spanish Paediatric Haemato-Oncology Group (SHOP/SEHOP). Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish Cooperative Study. SHOP/ALL-2005. British Journal of Haematology, 2013; 162: 419-21.

See more publications

Teaching

  • Collaborating lecturer on the Master's degree in Biomedicine at the University of Barcelona, since 2015.
  • Collaborating lecturer on the Master's degree in Pediatric Nursing, since 2013.
  • Coordinator, together with Dr. Ofelia Cruz, of the Master's degree in Pediatric Haematology at the University of Barcelona, since 2016.

SJD Barcelona Children's Hospital is a non-profit organization